guest ::
| Home > Publications database > A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity. > print |
| Home > Publications database > A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity. > print |
| 001 | 291282 | ||
| 005 | 20250401142757.0 | ||
| 024 | 7 | _ | |a 10.1038/s41541-024-00914-z |2 doi |
| 024 | 7 | _ | |a pmid:38926425 |2 pmid |
| 024 | 7 | _ | |a altmetric:166283428 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-01365 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Zhao, Xueer |0 P:(DE-He78)2d5634b584ebede249368464b907e28c |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity. |
| 260 | _ | _ | |a [London] |c 2024 |b Nature Publishing Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1719495243_13583 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:D335#LA:D335# |
| 520 | _ | _ | |a Persistent infection with high-risk human papillomavirus (HPV) is widely recognized as the primary cause of cervical and other malignant cancers. There are six licensed prophylactic vaccines available against HPV, but none of them shows any significant therapeutic effect on pre-existing infections or lesions. Thus, a prophylactic vaccine also endowed with therapeutic activity would afford protection regardless of the vaccine recipients HPV-infection status. Here, we describe the refinement and further potentiation of a dual-purpose HPV nanoparticle vaccine (hereafter referred to as cPANHPVAX) relying on eight different HPV L2 peptide epitopes and on the E7 oncoantigens from HPV16 and 18. cPANHPVAX not only induces anti-HPV16 E7 cytotoxic T-cell responses in C57BL/6 mice, but also anti-HPV18 E7 T-cell responses in transgenic mice with the A2.DR1 haplotype. These cytotoxic responses add up to a potent, broad-coverage humoral (HPV-neutralizing) response. cPANHPVAX safety was further improved by deletion of the pRb-binding domains of E7. Our dual-purpose vaccine holds great potential for clinical translation as an immune-treatment capable of targeting active infections as well as established HPV-related malignancies, thus benefiting both uninfected and infected individuals. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Zhang, Yueru |0 P:(DE-He78)35b8b312f24f786ff12489e8b1cf05ee |b 1 |u dkfz |
| 700 | 1 | _ | |a Trejo-Cerro, Oscar |b 2 |
| 700 | 1 | _ | |a Kaplan, Ecem |0 P:(DE-He78)64cd63747c118ca6ccef366d50a24e03 |b 3 |u dkfz |
| 700 | 1 | _ | |a Li, Zhe |0 P:(DE-He78)4cbe3abf3c7df5d7fbac1c945e4c2fce |b 4 |u dkfz |
| 700 | 1 | _ | |a Albertsboer, Femke |0 P:(DE-He78)8d1951818cf55b795407fc19811d7b56 |b 5 |
| 700 | 1 | _ | |a El Hammiri, Neyla |0 P:(DE-He78)18b47c4ee10637bff8bd8b11d046972f |b 6 |u dkfz |
| 700 | 1 | _ | |a Mariz, Filipe Colaço |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Banks, Lawrence |b 8 |
| 700 | 1 | _ | |a Ottonello, Simone |b 9 |
| 700 | 1 | _ | |a Müller, Martin |0 P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579 |b 10 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1038/s41541-024-00914-z |g Vol. 9, no. 1, p. 119 |0 PERI:(DE-600)2882262-6 |n 1 |p 119 |t npj vaccines |v 9 |y 2024 |x 2059-0105 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/291282/files/s41541-024-00914-z.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/291282/files/s41541-024-00914-z.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |o oai:inrepo02.dkfz.de:291282 |p VDB |p OpenAPC |p openCost |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)2d5634b584ebede249368464b907e28c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)35b8b312f24f786ff12489e8b1cf05ee |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)64cd63747c118ca6ccef366d50a24e03 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)4cbe3abf3c7df5d7fbac1c945e4c2fce |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)8d1951818cf55b795407fc19811d7b56 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)18b47c4ee10637bff8bd8b11d046972f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NPJ VACCINES : 2022 |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-04-12T15:11:19Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-04-12T15:11:19Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-04-12T15:11:19Z |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2023-04-12T15:11:19Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-24 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-24 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b NPJ VACCINES : 2022 |d 2023-08-24 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-08-24 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-08-24 |
| 915 | p | c | |a APC keys set |2 APC |0 PC:(DE-HGF)0000 |
| 915 | p | c | |a Local Funding |2 APC |0 PC:(DE-HGF)0001 |
| 915 | p | c | |a DFG OA Publikationskosten |2 APC |0 PC:(DE-HGF)0002 |
| 915 | p | c | |a DOAJ Journal |2 APC |0 PC:(DE-HGF)0003 |
| 920 | 2 | _ | |0 I:(DE-He78)D335-20160331 |k D335 |l Tumorvirus-spez. Vakzinierungsstrategie |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)D335-20160331 |k D335 |l Tumorvirus-spez. Vakzinierungsstrategie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D335-20160331 |k D335 |l Tumorvirus-spez. Vakzinierungsstrategie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D130-20160331 |k D130 |l B-Zell-Immunologie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D335-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D130-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a APC |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|